Maureen F. Zakowski

Overview

Best Publications

• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

  William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty

  5388
  Citations

• Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

  Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger

  5272
  Citations

• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely

  4261
  Citations

• Comprehensive genomic characterization of squamous cell lung cancers

  Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  3665
  Citations

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  2525
  Citations

• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller

  1922
  Citations

• Incidence of local recurrence and second primary tumors in resected stage I lung cancer

  Nael Martini;Manjit S. Bains;Michael E. Burt;Maureen F. Zakowski

  1393
  Citations

• Characterizing the cancer genome in lung adenocarcinoma

  Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner

  1304
  Citations

• Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

  Kerby Shedden;Jeremy M.G. Taylor;Steven A. Enkemann;Ming Sound Tsao

  1179
  Citations

• Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase

  Francis M. Sirotnak;Maureen F. Zakowski;Vincent A. Miller;Howard I. Scher

  979
  Citations

• Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

  Marissa N. Balak;Yixuan Gong;Gregory J. Riely;Romel Somwar

  973
  Citations

• Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

  Vincent A. Miller;Mark G. Kris;Neelain Shah;Jyoti Patel

  949
  Citations

• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  Gregory J. Riely;William Pao;Duy Khanh Pham;Allan R. Li

  859
  Citations

• The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

  Matthew Bott;Marie Brevet;Barry S Taylor;Shigeki Shimizu

  774
  Citations

• Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

  Raja M. Flores;Harvey I. Pass;Venkatraman E. Seshan;Joseph Dycoco

  692
  Citations

• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  Maria E. Arcila;Geoffrey R. Oxnard;Khedoudja Nafa;Gregory J. Riely

  687
  Citations

• Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

  Katerina Politi;Maureen F. Zakowski;Pang-Dian Fan;Emily A. Schonfeld

  679
  Citations

• Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

  Snjezana Dogan;Ronglai Shen;Daphne C. Ang;Melissa L. Johnson

  659
  Citations

• Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

  Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara

  541
  Citations

• Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

  Maria E. Arcila;Jamie E. Chaft;Khedoudja Nafa;Sinchita Roy-Chowdhuri

  484
  Citations